Thyroid – ASC Archived Cyto-econferences

Thyroid

   
Item Code: 3700-I

Item Name:  Thyroid Cytopathology: Common Dilemmas and Uncommon Diagnoses
Paul N. Staats, MD

Presentation date: December 8, 2015; Expires: December 8, 2018
Despite The Bethesda System, thyroid cytology continues to be challenging. This webinar will focus on the diagnosis of follicular-pattern lesions. We will review the clinical implications of the various diagnostic categories, discuss the role of molecular testing, and review less common entities that enter into the differential diagnosis of follicular-pattern thyroid lesions.

_________________________________________________________________________________________________________

   
Item Code: 3500-H

Item Name: Thyroid Fine Needle Aspiration Biopsy: The Contribution of Case Review and Second Opinions
Patricia G. Wasserman, MD

Presentation date: November 26, 2013; Expires: November 26,  2016
Inter-institutional consultation in pathology has shown to improve patient safety by detecting interpretative errors that may significantly impact clinical management. Opponents have alleged increased costs due to this consultative practice without considering potential cost of surgical complications, litigation expenses and cost avoidance from lost wages. This webinar will review the mayor sources of discrepancies in thyroid aspirations and explain the clinical impact of second opinions. A review of molecular testing as an adjunct tool to subjective morphologic criteria will be summarized.

_________________________________________________________________________________________________________

   
Item Code: 3400-I

Item Name: Molecular Diagnostics in Thyroid FNA Samples
Marina N. Nikiforova, MD

Presentation date: December 11, 2012; Expires: December 11, 2015
Fine needle aspiration (FNA) cytology provides a definitive diagnosis of benign or malignant disease in many cases, whereas about 25% of nodules are indeterminate, hindering most appropriate clinical management. Somatic mutations and other molecular alterations have been recognized as helpful diagnostic and prognostic markers for thyroid cancer. Molecular testing for BRAF, RAS, RET/PTC, and PAX8/PPARγ mutations is feasible in clinical FNA samples, helps to improve the diagnostic accuracy of FNA cytology, and offers a valuable tool for management of patients with thyroid nodules.